HOUSTON, June 12, 2020—ZZ Biotech today announced that the US Food and Drug Administration (FDA) has designated the investigation of the company’s experimental drug 3K3A-APC for the treatment of acute ischemic stroke as a Fast Track development program. ZZ Biotech’s 3K3A-APC is a genetically engineered variant of the naturally occurring activated Protein C, which plays…

Read More